SCHEMBL2940128

SCHEMBL2940128

CN(C)C1CCC(C(=O)Nc2c(C(=O)Nc3ccc(Cl)cn3)oc3ccccc23)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.59
▸ KMT2A Q03164 6/20 0.56
▸ MEN1 O00255 5/20 0.56
▸ POLB P06746 2/20 0.52
▸ RXFP1 Q9HBX9 2/20 0.52
▸ MAPT P10636 6/20 0.52
▸ HSD17B10 Q99714 5/20 0.52
▸ KDM4E B2RXH2 5/20 0.52
▸ TSHR P16473 5/20 0.52
▸ ALDH1A1 P00352 3/20 0.52
▸ HTT P42858 2/20 0.52
▸ HPGD P15428 1/20 0.52
▸ ALOX15 P16050 1/20 0.52
▸ GAA P10253 1/20 0.51
▸ TP53 P04637 3/20 0.50
▸ LMNA P02545 1/20 0.50
▸ DHODH Q02127 1/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50
▸ NPC1 O15118 1/20 0.46
▸ CASP3 P42574 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2940131 1.00 SMN1; SMN2 (0.59) SMN1; SMN2KMT2AMEN1POLBRXFP1
Hydrochloric Acid SCHEMBL2947082 0.99 SMN1; SMN2 (0.58) SMN1; SMN2KMT2AMEN1POLBRXFP1
Hydrochloric Acid SCHEMBL2947078 0.99 SMN1; SMN2 (0.58) SMN1; SMN2KMT2AMEN1POLBRXFP1
Iodide SCHEMBL2947683 0.94 SMN1; SMN2 (0.52) SMN1; SMN2KMT2AMEN1POLBRXFP1
SCHEMBL4327128 0.91 SMN1; SMN2 (0.59) SMN1; SMN2KMT2AMEN1POLBRXFP1
SCHEMBL4327123 0.91 SMN1; SMN2 (0.59) SMN1; SMN2KMT2AMEN1POLBRXFP1
SCHEMBL13744565 0.90 KMT2A (0.57) SMN1; SMN2KMT2AMEN1POLBRXFP1
SCHEMBL13744689 0.90 KMT2A (0.59) SMN1; SMN2KMT2AMEN1POLBRXFP1
SCHEMBL13744657 0.90 SMN1; SMN2 (0.54) SMN1; SMN2KMT2AMEN1POLBRXFP1
SCHEMBL2949585 0.90 SMN1; SMN2 (0.54) SMN1; SMN2KMT2AMEN1POLBRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1489078-B1 BENZOFURAN DERIVATIVE MITSUBISHI TANABE PHARMA CORP (JP) 2010-01-06 — — EP claimed
US-20090209511-A1 Benzofuran Derivatives KAWAGUCHI TAKAYUKI 2009-08-20 — — US claimed
US-7531537-B2 Benzofuran derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-05-12 — — US claimed
US-20050282808-A1 Benzofuran derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2005-12-22 — — US claimed
EP-1489078-A1 BENZOFURAN DERIVATIVE Tanabe Seiyaku Co., Ltd. (JP) 2004-12-22 — — EP claimed
EP-1489078-B1 BENZOFURAN DERIVATIVE MITSUBISHI TANABE PHARMA CORP (JP) 2010-01-06 — — EP disclosed
US-20090209511-A1 Benzofuran Derivatives KAWAGUCHI TAKAYUKI 2009-08-20 — — US disclosed
US-7531537-B2 Benzofuran derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-05-12 — — US disclosed
US-20090023918-A1 PROCESS FOR PREPARING 3-ACYLAMINOBENZOFURAN-2-CARBOXYLIC ACID DERIVATIVE SEKI MASAHIKO 2009-01-22 — — US disclosed
US-7439368-B2 Process for producing 3-acylaminobenzofuran-2-carboxylic acid derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-10-21 — — US disclosed
US-20060173188-A1 Process for producing 3-acylaminobenzofuran-2-carboxylic acid derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2006-08-03 — — US disclosed
EP-1640373-A1 PROCESS FOR PRODUCING 3-ACYLAMINOBENZOFURAN-2-CARBOXYLIC ACID DERIVATIVE TANABE SEIYAKU CO., LTD. (JP) 2006-03-29 — — EP disclosed
US-20050282808-A1 Benzofuran derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2005-12-22 — — US disclosed
EP-1489078-A1 BENZOFURAN DERIVATIVE Tanabe Seiyaku Co., Ltd. (JP) 2004-12-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282808-A1 Benzofuran derivative F12, F2, F11 SMN1; SMN2 3151/4885KMT2A 1500/4885MEN1 2756/4885
US-20090209511-A1 Benzofuran Derivatives F12, F2, F3 SMN1; SMN2 3067/4885KMT2A 1518/4885MEN1 2864/4885
US-20060173188-A1 Process for producing 3-acylaminobenzofuran-2-carboxylic acid derivative F12, F3, F11 SMN1; SMN2 4062/4885KMT2A 1346/4885MEN1 1551/4885
US-20090023918-A1 PROCESS FOR PREPARING 3-ACYLAMINOBENZOFURAN-2-CARBOXYLIC ACID DERIVATIVE F12, F3, F11 SMN1; SMN2 3833/4885KMT2A 1226/4885MEN1 1318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback